Sandoz Group AG (Sandoz Group AG) ROE % Adjusted to Book Value : 2.23% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG ROE % Adjusted to Book Value?

Sandoz Group AG's ROE % for the quarter that ended in Dec. 2023 was 3.54%. Sandoz Group AG's PB Ratio for the quarter that ended in Dec. 2023 was 1.59. Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 2.23%.

Sandoz Group AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Sandoz Group AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG ROE % Adjusted to Book Value Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

ROE % Adjusted to Book Value

0.56

Sandoz Group AG Quarterly Data
	Dec22	Dec23
ROE % Adjusted to Book Value	-	2.23

Competitive Comparison of Sandoz Group AG's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's ROE % Adjusted to Book Value falls into.

Sandoz Group AG ROE % Adjusted to Book Value Calculation

Sandoz Group AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.89%	/	1.59
	=	0.56%

Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	3.54%	/	1.59
	=	2.23%

Sandoz Group AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024